Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Sinomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sinomed Completes Enrollment in PIONEER-III pivotal US & Japanese Trial of the BuMA Supreme Coronary DES","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sinomed"}]

Sinomed

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sinomed Completes Enrollment in PIONEER-III pivotal US & Japanese Trial of the BuMA Supreme Coronary DES

Details:

SINOMED completed 1-year follow-up in the PIONEER-III trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). BuMA Supreme is Sinomed's second-generation DES with eG Coating, biodegradable polymer and sirolimus drug.

Lead Product(s): Sirolimus

Therapeutic Area: Cardiology/Vascular Diseases Product Name: BuMA Suprem

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY